Hemoglobin-S (HbS) is a variant of HbA. The variant arose as a result of GAG>GTG base transition at codon-6 of the β-globin gene on chromosome 11, which corresponds to a substitution of glutamic acid (polar amino acid) by valine (neutral amino acid) in position-6 of the β-globin chain (βGlu6Val). Consequently, HbS has less anionic potential, slower electrophoretic mobility, and reduced deoxygenated solubility that leads to polymerization and red cell sickling.

The prevalence of sickle β-gene in Nigeria and other tropical countries is as high as 25–30% or even higher. This is because the sickle cell trait (SCT) protects against severe malaria and confers survival advantage through natural selection, balanced polymorphism, and immunological and biochemical protective mechanisms against the malaria parasite. There are at least five different sickle β-gene mutation haplotypes. The Arab-Asian and Senegal haplotypes are associated with higher HbF levels and mild sickle cell disease (SCD), while the Benin, Banru, and Cameroon haplotypes are associated with lower HbF levels and severe SCD. Despite these haplotype variations, the diagnostic presence of HbS in people with SCT or SCD is uniformly based on two fundamental principles: physicochemical and electrochemical. The physicochemical principle is based on insolubility and polymerization of deoxy HbS, which forms the pathophysiologic basis for Hb solubility and red cell sickling tests. The electrochemical principle is based on charge-mobility alterations in HbS, which forms the pathophysiologic basis for Hb electrophoresis, isoelectric focusing, and chromatography.

SCD arises from the homozygous inheritance of HbS (HbSS) or double heterozygosity with another hemoglobinopathy (e.g., HbSC, HbSD, HbSE, HbSO, and HbSβthal). The clinical course of SCD is characterized by a painless period of relative well-being referred to as ‘steady-state’, which is intermittently interrupted by painful crises.

Apart from hemoglobin-S (HbS), there are other Hb variants (non-S sickling Hb variants) that cause sickle cell disease. However, the profiles of these non-S sickling Hb variants have neither been collated nor harmonized. A literature search revealed 14 non-S sickling Hb variants (HbC-Harlem, HbC-Zaguinchor, HbS-Travis, HbS-Antilles, HbS-Providence, HbS-Oman, HbS-Cameroon, HbS-South End, Hb Jamaica Plain, HbC-Ndjamen, HbS-Clichy, HbS-San Martin, HbS-Wake, and HbS-São Paulo). Generally, the non-S sickling Hb variants are double mutants with the HbS mutation (GAG>GTG: βGlu6Val) and additional β-chain mutations. Consequently, non-S sickling Hb variants give positive solubility and sickling tests, but they differ from HbS with respect to stability, oxygen affinity, and electro-chromatographic characteristics. Similarities and discrepancies between HbS and non-S sickling Hb variants create diagnostic pitfalls that can only be resolved by elaborate electro-chromatographic and/or genetic tests. It is therefore imperative that tropical hematologists should have a thorough understanding of these atypical sickling Hb variants. Collated and harmonized appraisal of the non-S sickling Hb variants have not been previously undertaken. Hence, this paper aims to provide a comprehensive but concise historical, genetic, comparative, diagnostic, and clinical overview of non-S sickling Hb variants. The elaborate techniques often required for precise diagnosis of non-S sickling Hb variants are regrettably not readily available in low resource tropical countries, which paradoxically carry the heaviest burden of sickling disorders. We strongly recommend that tropical countries should upgrade their diagnostic laboratory facilities to avoid misdiagnosis of these atypical Hb mutants.
periods referred to as ‘vaso-occlusive crisis’ (VOC). Clinical transition from steady-state to VOC is usually triggered by various factors that range from physiological (e.g., menstruation) to non-physiological (e.g., infection) factors on the one hand, and from psychological (e.g., mental stress) to physical (e.g., physical exhaustion) factors on the other hand. The red cells of persons with SCT have the HbAS phenotype, thus expressing both HbS (20–40%) and HbA (60–80%). The relative abundance of HbA in SCT red cells prevents sickling and undue hemolysis. Hence, SCT red cells have a normal life span, and SCT carriers have a normal life expectancy. Therefore, the HbS gene is genetically recessive, and SCT carriers are essentially asymptomatic except for the occasional episodes of renal papillary necrosis, splenic infarct at high altitude, or bone pain upon exposure to hematopoietic growth factors. With the largest black population of about 200 million, Nigeria is thought to carry the heaviest burden of sickling disorders globally; the frequency of SCT is 25–30% and prevalence of SCD is 2–3%. Since the official discovery of SCD by James B. Herrick in a black Grenadian dental student studying in the USA in 1910, HbS has remained the most thoroughly studied sickling Hb variant. Nonetheless, HbS is not the only Hb variant that sickles. Indeed, many sickling Hb variants other than HbS (i.e., non-S sickling Hb variants) have been discovered and reported. But the profiles of the non-S sickling Hb variants have neither been holistically collated nor chronologically harmonized. Hence, we conducted a literature search for non-S sickling Hb variants by using relevant search terms and sub-terms related to ‘red cell sickling and non-S sickling hemoglobin’ in PubMed, Medline, Google Scholar, and other search engines.

The non-S sickling Hb variants
There are presently 14 clinically significant non-S sickling Hb variants (discovered between 1966 and 2012), including HbC-Harlem, HbC-Ziguinchor, HbS-Travis, HbS-Antilles, HbS-Providence, HbS-Oman, HbS-Cameroon, HbS-South End, Hb Jamaica Plain, HbC-Ndjamena, HbS-Clichy, HbS-San Martin, HbS-Wake, and HbS-São Paulo. Similar to HbS, all non-S sickling Hb variants have normal alpha chains. However, the non-S sickling Hb variants differ from HbS because in addition to the Hbs gene mutation, each of them also has an additional single point mutation in the β-globin chain gene cluster on chromosome 11 (two point mutations on β-globin gene). Consequently, the non-S sickling Hb variants give positive solubility and sickling tests in similarity with HbS, but they may differ from HbS with respect to stability, oxygen affinity, and electro-chromatographic patterns. These discrepancies often produce a perplexing asynchrony between clinical features and laboratory findings, thus creating diagnostic pitfalls in evaluating patients affected by non-S sickling Hb variants. The diagnostic puzzles that shroud the non-S sickling Hb variants may therefore only be completely resolved by a combination of simple and complex diagnostic techniques, including red cell sickling, Hb solubility, stability and oxygen affinity tests, Hb tetramer and globin chain electrophoresis, isoelectric focusing, high-performance liquid chromatography (HPLC), and genetic studies. Although the non-S sickling Hb variant mutations are rare, they are nonetheless clinically significant for two reasons. Firstly, some non-S sickling variant mutations (e.g., HbS-Oman, HbS-Antilles, HbS-Jamaica Plain, and HbS-São Paulo) can cause SCD even in heterozygotes and are thus sometimes referred to as dominant or supersickling Hb variants. Secondly, any non-S sickling variant mutation can cause SCD if it is inherited as homozygous or co-inherited in double heterozygosity with other hemoglobinopathy mutations such as HbS, HbC, HbE, HbD, HbO, or β-thalassemia. The non-S sickling Hb variants should be kept in the mind of hematologists practicing in areas with a high prevalence of sickling disorders (tropical Africa, Mediterranean, and Asian countries) because they may cause diagnostically perplexing SCD. Hence, the need for a thorough understanding of these atypical sickling Hb variants. To the best of our knowledge, a collated and holistic appraisal of the various non-S sickling Hb variants has not been previously undertaken. Therefore, we aimed to provide a comprehensive but concise overview of the historical, genetic, comparative, diagnostic, and clinical perspectives of the non-S sickling Hb variants as outlined in Table 1.

Hemoglobin C-Harlem (â2â2: âGlu6Val, âAsp73Asn)
Hbc-Harlem is historically the first non-S sickling Hb variant to be described. It was reported by
in 1966 among African Americans living in Harlem. The mutant gene contains both the HbS mutation (βGlu6Val) and another mutation in the same β-globin gene (βAsp73Asn). The mutation βAsp73Asn is also associated with Hb Korle-Bu, a well-characterized clinically innocuous Hb that electrophoretically migrates like HbS, but does not sickle. Hence, it is highly likely that a chromosomal crossing-over between HbS gene and Hb Korle-Bu gene was responsible for producing the HbC-Harlem gene, which consequently contains both βGlu6Val and βAsp73Asn mutations. These double mutations were also described in a Hb variant previously designated as HbC-Georgetown, which was subsequently identified as identical to HbC-Harlem. Like other non-S sickling Hb variants, HbC-Harlem gives positive sickling and solubility tests, which are pathophysiologic reflections of the βGlu6Val mutation. Nonetheless, HbC-Harlem has relatively lower thermal and mechanical stability compared with HbS. Moreover, HbC-Harlem migrates like HbC in alkaline electrophoresis, hence HbSC-Harlem disease can easily be misdiagnosed as HbSC disease as previously reported in the literature. The similarity in alkaline electrophoretic mobility between HbC and HbC-Harlem makes it possible to misdiagnose HbCC as HbCC-Harlem if alkaline electrophoresis is used as the sole diagnostic technique. But this misdiagnosis and diagnostic pitfall can be clinically clarified by the presence of VOC in HbCC-Harlem, whereas HbCC disease does not cause VOC. Diagnostic issues for HbC-Harlem can be further clarified by more detailed investigations, which would reveal

| Serial No. | Hemoglobin     | First report (References) | Amino acid substitutions (Codon mutations) | Genetic and clinical expression |
|------------|----------------|---------------------------|-------------------------------------------|--------------------------------|
| 1          | HbC-Harlem     | Bookchin et al., 1966     | βGlu6Val (GAG>GTG), βAsp73Asn (GAT>AAT)   | Recessive. Causes SCD if coinherited with other abnormal hemoglobin. |
| 2          | HbC-Ziguinchor | Goossens et al., 1975     | βGlu6Val (GAG>GTG), βPro58Arg (CCT>CGT)   | Recessive. Causes SCD if coinherited with other abnormal hemoglobin. |
| 3          | HbS-Travis     | Moo-Penn et al., 1977     | βGlu6Val (GAG>GTG), βAla142Val (GCC>GTC)  | Recessive. SCD due to homozygous or double heterozygous inheritance not reported. |
| 4          | HbS-Antilles   | Monplaisir et al., 1986   | βGlu6Val (GAG>GTG), βVal23Ile (GTT>ATT)   | Dominant. Causes severe SCD if coinherited with other abnormal hemoglobin. |
| 5          | HbS-Providence | Gale et al., 1988         | βGlu6Val (GAG>GTG), βLys82Asn/Asp (AAG>AA T) | Recessive. SCD due to homozygous or double heterozygous inheritance not reported. |
| 6          | HbS-Oman       | Langdown et al., 1989     | βGlu6Val (GAG>GTG), βGlu121Lys (GAA>AAA) | Dominant. Causes severe SCD if coinherited with HbS. |
| 7          | HbS-Cameroon   | Bundgaard et al., 2004    | βGlu6Val (GAG>GTG), βGlu90Lys (GAG>AAG)  | Recessive. SCD due to homozygous or double heterozygous inheritance not reported. |
| 8          | HbS-South End  | Luo et al., 2004          | βGlu6Val (GAG>GTG), βLys132Asn (AAA>ACC) | Simple heterozygote not reported. SCD due to double heterozygous HbS/HbS-South End reported in the index case. |
| 9          | Hb Jamaica Plain | Geva et al., 2004        | βGlu6Val (GAG>GTG), βLys68Phe (CTC>TTC)  | Dominant. Would cause severe SCD if coinherited with other hemoglobinopathies. |
| 10         | HbC-Ndjamena   | Ducrocq et al., 2006      | βGlu6Val (GAG>GTG), βThr37Gly (TGG>GCG)  | Recessive. Two cases of SCD due to double heterozygous HbS/HbC-Ndjamena reported. |
| 11         | HbS-Clichy     | Zanella-Cleon et al., 2009 | βGlu6Val (GAG>GTG), βLys8Thr (AAA>ACA)    | Recessive. Homozygous or double heterozygous SCD not reported. |
| 12         | HbS-San Martin | Feliu-Torres et al., 2010 | βGlu6Val (GAG>GTG), βLeu105Pro (CTC>CAC) | Dominant for hemolysis but recessive for pain. Homozygous or double heterozygous SCD not reported. |
| 13         | HbS-Wake       | Kutlar et al., 2010       | βGlu6Val (GAG>GTG), βAsn139Ser (AA T>AGT) | Recessive. One case of SCD due to double heterozygous HbS/HbS-Wake reported. Homozygous not reported. |
| 14         | HbS-São Paulo  | Jorge et al., 2012       | βGlu6Val (GAG>GTG), βLys65Glu (AAG>GAG)  | Dominant. Would cause severe SCD if coinherited with other abnormal hemoglobins. |
that HbC-Harlem, unlike HbC, migrates as HbS in acid pH electrophoresis and as HbA2 in isoelectric focusing, and elutes with HbA2 in anion exchange chromatography.\textsuperscript{37-39} HbC-Harlem trait is genetically recessive as the heterozygous state is essentially benign, except for the occurrence of hyposthenuria,\textsuperscript{40} which is similar to the renal manifestation of HbS trait.\textsuperscript{10} However, when HbC-Harlem is co-inherited in a double heterozygous combination with HbS or other hemoglobinopathies, the affected individuals would present as severe SCD with hemolysis, recurrent VOC and/or hematuria,\textsuperscript{40-42} which are similar to the hemolytic, VO, and renal manifestations of classical SCD.\textsuperscript{10} Because of the rarity of HbC-Harlem, its effect on pregnancy has not been adequately studied. Nevertheless, a single case report of a pregnant woman of African descend with the double heterozygous combination of HbC and HbC-Harlem suggested that HbCC-Harlem disease had adverse effects on maternal morbidity and fetal growth and survival,\textsuperscript{43} a finding that is comparable to the effect of classical SCD on pregnancy.\textsuperscript{44}

\textbf{Hemoglobin C-Ziguinchor (\(\alpha2\alpha2: \alpha\text{Glu6Val, \alphaPro58Arg}\))}

HbC-Ziguinchor was the second non-S sickling Hb variant to be described. HbC-Ziguinchor was first detected in a 40-year-old African man in Dakar, Senegal, by Goossens et al.\textsuperscript{21} in 1975. The \(\beta\)-globin gene for HbC-Ziguinchor contains both the HbS substitution mutation (\(\beta\text{Glu6Val}\)) and an additional second substitution mutation (\(\beta\text{Pro58Arg}\)).\textsuperscript{21} The second substitution mutation (\(\beta\text{Pro58Arg}\)) had previously been described in association with Hb-Dhofar (discovered in a South Arabian Vedood from the Al-Qara mountains of Dhofar), and in association with Hb-Yukahashi (discovered in a Japanese individual).\textsuperscript{45} Both Hb-Dhofar and Hb-Yukahashi have since been regarded as one and same Hb variant since they are genetically identical and phenotypically similar even though the two index cases were discovered in two different racial settings (i.e., Arab and Japanese races).\textsuperscript{45} It is presumed that HbC-Ziguinchor might have arisen as a result of chromosomal crossing-over involving the \(\text{Hbs}\) gene and Hb-Dhofar/Yukahashi gene.\textsuperscript{21} HbC-Ziguinchor does not have any abnormalities in either its heat stability or isopropanol solubility. Still, it retains the fundamental physical abnormalities of HbS (i.e., sickling, gelation, and relative insolubility in its deoxy form).\textsuperscript{21,46} HbC-Ziguinchor is distinguishable from HbS as it migrates slightly cathodal to both HbA and HbC in alkaline cellulose acetate electrophoresis.\textsuperscript{21,46} However, in acidic agar gel electrophoresis, HbC-Ziguinchor is indistinguishable from HbS, and it elutes after HbA2 in anion exchange chromatography.\textsuperscript{21,46} Diagnostic issues regarding this abnormal Hb variant can be further resolved by globin chain electrophoresis, which consistently reveals that the \(\beta\)-globin chain of HbC-Ziguinchor moves more anodally than that of HbC in both alkaline and acidic media.\textsuperscript{21,46} The clinical features of HbC-Ziguinchor have not been adequately evaluated because of the rarity of the variant. However, a limited clinical experience had shown that HbC-Ziguinchor trait is genetically recessive as the heterozygote does not present any hematological or clinical manifestation and is completely asymptomatic.\textsuperscript{47} Conversely, when HbC-Ziguinchor is co-inherited with HbS or other hemoglobinopathies such as HbC or \(\beta\)-thalassemia trait, the affected patients present with severe hemolysis and VOC that are indistinguishable from classical forms of SCD.\textsuperscript{47} Moreover, a single case report of co-inherited HbC-Ziguinchor and hereditary persistence of fetal Hb revealed an elevated level of HbF with a commensurate reduction in the frequency of VOC.\textsuperscript{48}

\textbf{Hemoglobin S-Travis (\(\alpha2\alpha2: \alpha\text{Glu6Val, \alphaAla142Val}\))}

HbS-Travis is the third non-S sickling Hb variant to be described after HbC-Harlem and HbC-Ziguinchor. HbS-Travis was first discovered in five members of a Black family in Travis, USA, as reported by Moo-Penn et al.\textsuperscript{22} in 1977. All of the five studied family members were heterozygotes. Genetic analysis revealed that HbS-Travis has two amino acid substitutions in the \(\beta\)-globin chain that include \(\beta\text{Glu6Val}\) and \(\beta\text{Ala142Val}\),\textsuperscript{22} which most probably arose as a result of genetic crossing-over between HbS gene (\(\beta\text{Glu6Val}\)) on chromosome 11 and another chromosome carrying the \(\beta\text{Ala142Val}\) mutation.\textsuperscript{22} Electrophoretically, HbS-Travis moves to a position between HbS and HbF at alkaline pH, but at acidic pH it moves between HbA and HbS.\textsuperscript{22} Nonetheless, HbS-Travis and HbA can be separated by anion exchange chromatography as it elutes immediately before HbA.\textsuperscript{22} Functional
studies on HbS-Travis revealed that in addition to insolubility, polymerization, and sicklability of the deoxy form, HbS-Travis has significantly decreased affinity for 2,3-diphosphoglycerate (2,3-DPG) with a commensurate increase in oxygen affinity.\textsuperscript{22} HbS-Travis is, therefore, functionally a high oxygen affinity Hb variant.\textsuperscript{22} Moreover, HbS-Travis tends to undergo auto-oxidation and is relatively unstable.\textsuperscript{22} The mean gelling concentration of HbS-Travis is similar to that of HbS, but the quantity of HbS-Travis in the heterozygote (HbS-Travis trait) is considerably low at about 14\% (cf. about 40\% HbS in HbS trait), hence HbS-Travis heterozygotes are essentially asymptomatic, and the trait is thus genetically recessive.\textsuperscript{22} SCD due to HbS-Travis homozygosity or its coinheritance (double heterozygosity) with HbS or other hemoglobinopathies have not been seen or reported in the literature to date. It may be presumed that HbS-Travis SCD (if found in the future) would be generally mild to moderate in severity because HbS-Travis has high oxygen affinity\textsuperscript{22} and would predictably simulate the anti-sickling effect of HbF\textsuperscript{40} by ‘auto-protecting’ itself from excessive desaturation, polymerization, and sickling. However, this prediction can only be ascertained if HbS-Travis SCD is eventually discovered in any patient in the future.

**Hemoglobin S-Antilles (α2α2: αGlu6Val, αVal23Ile)**

HbS-Antilles is the fourth non-S sickling Hb variant to be described in the literature. It was first found in members of a family from Martinique in French West Indies as reported by Monplaisir et al.,\textsuperscript{23} in 1986. HbS-Antilles is a double mutant with two amino acid substitutions in the β-globin chain, which includes βGlu6Val and βVal23Ile that most probably arose as a result of genetic crossing-over between HbS gene (βGlu6Val) on chromosome 11 and another chromosome carrying the βVal23Ile mutation.\textsuperscript{23} Chromosomal analysis revealed that the βVal23Ile mutation initially occurred on another chromosome 11 bearing β-globin gene of the Benin type haplotype that was subsequently juxtapositioned to the HbS gene (βGlu6Val), thus generating the double mutant HbS-Antilles.\textsuperscript{23} The electrophoretic mobility of HbS-Antilles is identical to HbS in a standard alkaline medium but slightly slower than HbS in isoelectric focusing.\textsuperscript{23} HbS-Antilles and HbA can be readily separate by chromatography.\textsuperscript{23} Functional studies on HbS-Antilles shows a normal Bohr effect, but the oxygen affinity of HbS-Antilles is significantly decreased, and the solubility of deoxy HbS-Antilles is considerably less than that of deoxy HbS.\textsuperscript{23} Consequently, HbS-Antilles gives a stronger positive sickling test.\textsuperscript{23} The quantity of HbS-Antilles in the heterozygotes was between 40\% and 50\%.\textsuperscript{23} In comparison with HbS, HbS-Antilles has a higher quantity in heterozygotes, lower oxygen affinity, greater insolubility in the deoxy form, higher polymerization tendency, and a faster sickling rate.\textsuperscript{23} Consequently, unlike HbS trait, HbS-Antilles trait is associated with symptoms of hemolysis and VO pain consistent with mild to moderate SCD, which makes HbS-Antilles a genetically dominant trait.\textsuperscript{23} Homozygous HbS-Antilles SCD has not been reported in the literature to date. But severe SCD can occur if HbS-Antilles is coinherited with HbS or other hemoglobinopathies. For example, severe SCD had occurred when HbS-Antilles was coinherited in combination with HbC and HbS.\textsuperscript{23} The hematological and pathological effects of HbS-Antilles were later studied in detail using transgenic mice models produced by genomic insertions of HbS-Antilles gene to produce a simple heterozygote (HbAS-Antilles)\textsuperscript{51} or in combination with HbS gene to produce a double heterozygote (HbSS-Antilles).\textsuperscript{52} Both transgenic models exhibited hematological parameters and multiple organ damage pathologies that was similar to the hematological and pathological features of classical SCD as reported in humans.\textsuperscript{51,52} The hematological anomalies and painful symptoms documented in the simple heterozygous index patients (HbS-Antilles traits),\textsuperscript{23} simple heterozygous transgenic mice,\textsuperscript{51} and double heterozygous (HbSS-Antilles) mice\textsuperscript{52} have confirmed the dominant nature of HbS-Antilles trait and its ability to cause SCD in both heterozygous and double heterozygous individuals.

**Hemoglobin S-Providence (α2α2: αGlu6Val, αLys82Asn/Asp)**

HbS-Providence is the fifth non-S sickling Hb variant to be described. It was discovered in a woman of west African descent by Gale et al.,\textsuperscript{24} in 1988. HbS-Providence is a double mutant as genetic analysis of the affected chromosome 11 revealed the presence of HbS mutation (βGlu6Val) and a second β-chain mutation (Hb-Providence mutation: βLys82Asn/Asp).\textsuperscript{24} The Hb-Providence mutation primarily
The sickled red in an Omani Arab as reported by Langdown et al. to be described in the literature. It was first found in persons of African descent, and subsequent cases were found in persons of apparently pure European descent. Based on genetic permutations and probabilities, HbS-Providence might have arisen due to crossing-over between chromosomes that carry the HbS and Hb-Providence genes. Although HbS-Providence exhibits positive sickling and solubility tests, it is indistinguishable from HbA by routine electrophoresis at either alkaline or acidic pH. Nevertheless, the β-globin chains of HbA, HbS, and HbS-Providence can be separated and identified by further testing with chromatography. Therefore, any case of positive sickling or solubility test that presents as HbAA on electrophoresis must be considered a possible case of HbS-Providence and be subjected to further investigations. The heterozygous index case of HbS-Providence as described by Gale et al. had < 50% HbS-Providence and was hematologically and clinically normal, which suggested that HbS-Providence mutation is a recessive trait. SCD due to homozygous or double heterozygous inheritance of HbS-Providence with HbS have not been reported. However, it can be presumed that HbS-Providence SCD (if seen in the future) would be generally mild to moderate in severity because HbS-Providence has functional impairment of 2,3-DPG binding with resultant high oxygen affinity. Similar to other high-affinity non-S sickling Hb variants, such as HbS-Travis, HbS-Providence would be expected to ‘auto-protect’ itself from excessive desaturation, polymerization and sickling if inherited as homozygous or double heterozygous SCD in the future.

**Hemoglobin S-Oman (α2α2: Glu6Val, Glu121Lys)**

HbS-Oman is the sixth non-S sickling Hb variant to be described in the literature. It was first found in an Omani Arab as reported by Langdown et al. in 1989. Genetic analysis revealed that HbS-Oman is a double mutant that carries two mutations (Glu6Val and Glu121Lys) in the β-globin chain. Because both valine and lysine are non-polar amino acids, HbS-Oman incurs an aggregate loss of four negative charges per Hb molecule and is thus electrophoretically slower than HbS, which has an aggregate loss of only two charges per Hb molecule. The Glu121Lys mutation had previously been described in HbO-Arab. Hence, HbS-Oman most probably arose as a result of genetic crossing-over and gene translocation between two chromosomes: one chromosome carrying the HbS gene (Glu6Val) and the other chromosome carrying the HbO-Arab gene (Glu121Lys), resulting in the production of HbS-Oman chromosome, which carries both genes. The quantity and proportion of HbS-Oman in the heterozygote red cell are affected by the coinheritance of the alpha thalassemia trait. Hence, the proportion of HbS-Oman in the heterozygote red cells is 14–20%, and heterozygotes with concurrent alpha thalassemia trait tend to have lower quantity of HbS-Oman in their red cells. In similarity with HbS-Antilles, the solubility of the deoxy HbS-Oman is much lower than that of deoxy HbS, which makes both Hb variants (HbS-Antilles and HbS-Oman) have stronger sickling tendencies (compared with HbS) and behave as super-sickling variants with dominant hemolytic and VO clinical manifestations even in the heterozygotes. Moreover, HbS-Oman is particularly highly sicklable even in the heterozygote because the effect of the sickle mutation (Glu6Val) is enhanced by the adjacent HbO-Arab mutation (Glu121Lys), which is known for its capability to cause red cell dehydration and raise mean corpuscular Hb concentration. Despite having positive sickling and solubility tests, HbS-Oman is slower and separates distinctly from HbS, HbA, and HbF in both alkali and acid gel electrophoresis. Nonetheless, HbS-Oman moves as HbC in alkaline and acid electrophoresis and elutes in the same position as HbC in HPLC. The sickled red cells seen in the peripheral blood of patients with heterozygous or double heterozygous HbS-Oman SCD have a peculiar centrally bulbous configuration that is reminiscent of the ‘yarn-knitting needle’ or ‘Napoleon Hat’, which are morphologically pathognomonic and microscopically diagnostic of HbS-Oman disease.
HbS-Oman disease has not been previously reported. Nonetheless, HbS-Oman has been known to cause severe SCD with hemolytic and VO clinical features if it is coinherited in double heterozygosity with HbS as previously reported.\textsuperscript{57-59} 

**Hemoglobin S-Cameroon (â2â2: âGlu6Val, âGlu90Lys)**

HbS-Cameroon is the seventh non-S sickling Hb variant to be described. It was first reported by Bundgaard et al,\textsuperscript{26} in a Cameroonian in 2004. HbS-Cameroon is a double mutant that carries two mutations (βGlu6Val and βGlu90Lys) in the β-globin chain.\textsuperscript{26} HbS-Cameroon has only been described in the heterozygous state as reported in the index case.\textsuperscript{26} Absence of abnormal hematological features and VO symptoms in the index case would suggest that HbS-Cameroon is a genetically recessive trait.\textsuperscript{26} Nonetheless, because it bears the βGlu6Val substitution, HbS-Cameroon is electrophoretically slow and is positive by solubility and sickling tests.\textsuperscript{26} However, HbS-Cameroon can be distinguished from HbS by chromatography.\textsuperscript{26} Moreover, HbS-Cameroon has reduced oxygen affinity because the second mutation (βGlu90Lys) is identical to the mutation previously described in Hb-Agenogi (a rare variant reported in Japanese, Africans, Hungarians, and Argentineans), which is associated with low oxygen affinity.\textsuperscript{60} Hence, HbS-Cameroon is functionally a low oxygen affinity variant (as is the case with HbS-Antilles), and would therefore be vulnerable to excessive desaturation and polymerization, both of which would lead to severe SCD if HbS-Cameroon is inherited as homozygous (HbS-Cameroon/HbS-Cameroon) or double heterozygous with HbS (HbS-Cameroon/HbS) in the future.

**Hemoglobin S-South End (â2â2: âGlu6Val, âLys132Asn)**

HbS-South End is the eighth non-S sickling Hb variant to be described. It was found in an African American patient of Ugandan descent as reported by Luo et al,\textsuperscript{27} in 2004. Similar to other non-S sickling mutants, HbS-South End is a double mutant that carries two mutations (βGlu6Val and βLys132Asn) in the β-globin chain.\textsuperscript{27} Because HbS-South End bears the βGlu6Val, it produces positive results by solubility and sickling tests.\textsuperscript{27} In addition, HbS-South End mimics HbA on alkaline and acid electrophoresis (as is the case with HbS-Providence) and by HPLC. Still, it migrates as HbF on capillary zone electrophoresis and isoelectric focusing. This situation creates major diagnostic pitfalls unless further testing by Hb tetramer and globin chain electrophoresis or DNA and genomic analyses are undertaken.\textsuperscript{27} The index patient presented as a case of SCD with double heterozygous coinheritance of HbS/HbS-South End.\textsuperscript{27} Unfortunately, other family members of the index case were not available for study.\textsuperscript{27} Consequently, simple heterozygotes for HbS-South End have not been described; hence no categorical statement can be made on whether the HbS-South End mutation is a recessive or dominant trait. Moreover, patients with homozygous HbS-South End SCD have also not been reported in the literature. So the only reported case of HbS-South End is the compound heterozygous (HbS/HbS-South End) index case.\textsuperscript{27} Interestingly, the index case presented as a severe case of SCD that was associated with severe hemolytic and VO symptoms because the second mutation (βLys132Asn) in HbS-South End is identical to the mutation in Hb Yamakata, a low oxygen affinity Hb variant discovered in a Japanese family in 1990.\textsuperscript{27,61} The amino acid substitution resulting from the βLys132Asn mutation in Hb Yamakata facilitates 2,3-DPG binding, which functionally lowers oxygen affinity, increases the rate of oxygen release and enhance desaturation.\textsuperscript{61} Therefore, HbS-South End is functionally a low oxygen affinity variant (as is the case with HbS-Antilles and HbS-Cameroon) and would thus be vulnerable to excessive desaturation and polymerization, both of which would increase red cell sickling and ultimately produce a clinically severe SCD as reported in the index patient.\textsuperscript{27}

**Hemoglobin Jamaica Plain (â2â2: âGlu6Val, âLeu68Phe)**

Hb Jamaica Plain was the 9th non-S sickling Hb variant described in the literature. It was found in an African American patient of Puerto Rican descent as reported by Geva et al,\textsuperscript{28} in 2004. Similar to other non-S sickling mutants, HbS-South End is a double mutant that carries two mutations (βGlu6Val and βLys132Asn) in the β-globin chain.\textsuperscript{27} Because HbS-South End bears the βGlu6Val, it produces positive results by solubility and sickling tests.\textsuperscript{27} In addition, HbS-South End mimics HbA on alkaline and acid electrophoresis (as is the case with HbS-Providence) and by HPLC. Still, it migrates as HbF on capillary zone electrophoresis and isoelectric focusing. This situation creates major diagnostic pitfalls unless further testing by Hb tetramer and globin chain electrophoresis or DNA and genomic analyses are undertaken.\textsuperscript{27} The index patient presented as a case of SCD with double heterozygous coinheritance of HbS/HbS-South End.\textsuperscript{27} Unfortunately, other family members of the index case were not available for study.\textsuperscript{27} Consequently, simple heterozygotes for HbS-South End have not been described; hence no categorical statement can be made on whether the HbS-South End mutation is a recessive or dominant trait. Moreover, patients with homozygous HbS-South End SCD have also not been reported in the literature. So the only reported case of HbS-South End is the compound heterozygous (HbS/HbS-South End) index case.\textsuperscript{27} Interestingly, the index case presented as a severe case of SCD that was associated with severe hemolytic and VO symptoms because the second mutation (βLys132Asn) in HbS-South End is identical to the mutation in Hb Yamakata, a low oxygen affinity Hb variant discovered in a Japanese family in 1990.\textsuperscript{27,61} The amino acid substitution resulting from the βLys132Asn mutation in Hb Yamakata facilitates 2,3-DPG binding, which functionally lowers oxygen affinity, increases the rate of oxygen release and enhance desaturation.\textsuperscript{61} Therefore, HbS-South End is functionally a low oxygen affinity variant (as is the case with HbS-Antilles and HbS-Cameroon) and would thus be vulnerable to excessive desaturation and polymerization, both of which would increase red cell sickling and ultimately produce a clinically severe SCD as reported in the index patient.\textsuperscript{27}
HbS by isoelectric focusing and HPLC. However, Hb Jamaica Plain was identified in the index case by DNA sequencing of the patient's β-globin gene, which revealed that her maternal β-globin allele was normal while her paternal allele had not only the expected HbS trait mutation (βGlu6Val) but also a second, charge-neutral mutation, (βLeu68Phe), which the child must have acquired through spontaneous germ-line mutation. Hb Jamaica Plain is therefore a charge-neutral double-mutant (βGlu6Val and βLeu68Phe) Hb variant that is difficult to detect without DNA sequencing since it cannot be distinguished from HbS by isoelectric focusing or HPLC. Hb Jamaica Plain may thus be responsible for sporadic and inexplicable cases of clinically severe VO symptoms in persons with presumed 'HbS trait' if only basic electrophoretic and chromatographic techniques are used for diagnosis. It is noteworthy that the second mutation (βLeu68Phe) was previously reported as an isolated finding in Hb Rockford, now known as Hb Loves Park, which is associated with low oxygen affinity. Consequently, Hb Jamaica Plain is functionally a low oxygen affinity variant (as is the case with Antilles, HbS-Cameroon, and HbS-South End) characterized by a marked decrease in oxygen affinity that is even lower than that of HbS Antilles. This functional characteristic makes Hb Jamaica Plain particularly susceptible to deoxygenation, desaturation, and polymerization with a resultant severe and dominant clinical phenotype that manifests as severe SCD even in the heterozygous state as seen in the index case. Hb Jamaica Plain is a member of the so-called dominant/super-sickling non-S Hb variants, with the other members being HbS-Antilles and HbS-Oman and HbS-São Paulo.

Hemoglobin C-Ndjamen (α2α2: αGlu6Val, αTrp37Gly)

HbC-Ndjamen is chronologically the 10th non-S sickling Hb variant to be described. It was discovered in a Chadian patient with double heterozygous SCD due to coinheritance of HbS/HbC-Ndjamen as described by Ducrocq et al. in 2006. Another case of double heterozygous HbS/HbC-Ndjamen SCD was also reported in 2011 by Bouzid et al. HbC-Ndjamen is a double mutant as genetic analysis of the affected chromosome 11 revealed the presence of HbS mutation (βGlu6Val) and a second β-chain mutation (βTrp37Gly). The βTrp37Gly has earlier been reported by Owen et al. in 1993 as an isolated non-sickling mutant allele in a Hb variant called Hb Howick, which is functionally characterized by impairment of 2,3-DPG binding and high oxygen affinity. In similarity with HbS, HbC-Ndjamen gives positive solubility and sickling tests. However, HbC-Ndjamen is distinguishable from HbS as it migrates close to (but a little faster than) HbC in alkaline cellulose acetate electrophoresis and isoelectric focusing, and it elutes faster than HbS in HPLC. The HbS/HbC-Ndjamen patient reported by Bouzid et al. inherited the HbS allele from the mother and the HbC-Ndjamen allele from the father; both parents were clinically asymptomatic, thus HbC-Ndjamen allele is a genetically recessive trait. Patients with homozygous HbC-Ndjamen SCD have not been reported in the literature. Nonetheless, the two aforementioned cases of SCD due to coinheritance of HbS/HbC-Ndjamen were associated with mild to moderate hemolytic and VO symptoms because the second mutation (βTrp37Gly) in HbC-Ndjamen is identical to the mutation in Hb Howick, which is associated with high oxygen affinity. Hence, HbC-Ndjamen is essentially a high oxygen affinity variant (as is the case with HbS-Travis and HbS-Providence), and would therefore pathophysiologically auto-protect itself from excessive desaturation and polymerization, both of which would reduce red cell sickling and ultimately produce a clinically non-severe SCD as reported in the two index patients.

Hemoglobin S-Clichy (α2α2: αGlu6Val, αLys8Thr)

HbS-Clichy is the 11th non-S sickling Hb variant that was discovered in an African European. It was first reported by Zanella-Cleon et al. in 2009. Similar to other non-S sickling mutants, HbS-Clichy is a double mutant that carries two mutant substitutions (βGlu6Val and βLys8Thr) in the β-globin chain. It was detected as a slow variant by routine electrophoretic techniques and HPLC in the asymptomatic heterozygous state as seen in the index case. HbS-Clichy produces positive solubility and sickling tests. However, DNA and genomic analyses showed that in addition to the glutamic acid substitution by valine at codon 8, the lysine at codon 6 was replaced by threonine. The absence of hemolytic and VO symptoms in the index heterozygote suggests that HbS-Clichy...
allele is a genetically recessive trait. Nonetheless, HbS-Clichy would most probably cause clinically symptomatic SCD if it is inherited as homozygous or co-inherited as double heterozygous with HbS or other hemoglobinopathies in the future.

**Hemoglobin S-San Martin (á2á2: áGlu6Val, áLeu105Pro)**

HbS-San Martin is the 12th non-S sickling Hb to be described. It was discovered in a 10-year-old boy in an Argentinean family from San Martin, Buenos Aires, Argentina as described by Feliu-Torres et al. in 2010. HbS-San Martin is a double mutant characterized by the presence of one mutation on exon-1 [GAG>GTG] that corresponds to HbS [βGlu6Val] substitution, and the second mutation on exon-3 [CTC>CCC], which corresponds to βLeu105Pro substitution. In addition to giving positive solubility and sickling tests, HbS-San Martin migrated in similarity with HbS as depicted by alkaline cellulose and acid pH agar gel electrophoresis. Moreover, heat stability and isopropanol tests were positive indicating that HbS-San Martin is an unstable Hb variant. The index case was a simple heterozygote for the HbS-San Martin mutation, which he inherited from his mother, in whom the mutation might have occurred spontaneously. Both the index case and his mother revealed the presence of pallor and jaundice, but neither had any history of pain or VOC. These findings suggest that HbS-San Martin is recessive with respect to pain and VO symptoms. Still, it is dominant with respect to hemolytic manifestations. It can easily be deduced that the dominant hemolytic manifestation of HbS-San Martin is a reflection of the configurational attributes of its second mutation (βLeu105Pro) in which the substitution of leucine by proline interferes with the structural stability of the Hb molecule resulting in hemolytic clinical manifestations that are typical of unstable Hb variants. However, HbS-San Martin may cause typical SCD (with both hemolytic and VO manifestations) if it is inherited as homozygous or co-inherited as double heterozygous with HbS or other hemoglobinopathies in the future. Hematologists should therefore raise their index of suspicion for HbS-San Martin on any patient that presents as a case of hemolytic anemia (devoid of pain) with Hb instability, positive sickling test, and electrophoretic pattern suggestive of HbS trait.

**Hemoglobin S-Wake (á2á2: áGlu6Val, áAsn139Ser)**

HbS-Wake is the 13th non-S sickling Hb variant to be described. It was discovered in a 14-year-old African-American boy who was diagnosed with SCD as reported by Kutlar et al. in 2010. Like other non-S sickling Hb variants, HbS-Wake is a double mutant that carries two mutant substitutions (βGlu6Val and βAsn139Ser) in the β-globin chain. The presence of the βGlu6Val substitution confers upon HbS-Wake positive solubility and sickling tests. Moreover, HbS-Wake depicts slow electrophoretic mobility in alkaline and acid media but can be differentiated from HbS by isoelectric focusing and HPLC. Laboratory tests showed that the index patient was a compound heterozygote for HbS-Wake with a double mutation (βGlu6Val and βAsn139Ser) on one of his chromosome 11 and a single HbS mutation (βGlu6Val) on the other chromosome 11, leading to HbSS-Wake SCD. The index patient with HbSS-Wake SCD was found to have co-inherited homozygous α(+) thalassemia trait, which resulted in lower mean corpuscular hemoglobin concentration (MCHC). Consequently, the patient had relatively mild hemolytic and VO features of SCD, which is consistent with the fact that low MCHC reduces the intensity of HbS polymerization and red cell sickling in SCD. The absence of hematological and clinical manifestations in the HbS-Wake heterozygous parent of the index patient suggested that HbS-Wake trait is genetically recessive.

**Hemoglobin S-São Paulo (á2á2: áGlu6Val, áLys65Glu)**

HbS-São Paulo is the 14th and the latest and most recently described non-S sickling Hb variant. It was discovered in an 18-month-old Brazilian male by Jorge et al. in 2012. Chromosomal and genetic analysis of chromosome 11 revealed that HbS-São Paulo is a double mutant characterized by the dual occurrence of GAG>GTG transition at codon-6 that corresponds to HbS [βGlu6Val] substitution and an AAG>GAG transition at codon-65, which corresponds to βLys65Glu substitution at the 65th position of the β-globin chain. The index case was heterozygous for HbS-São Paulo, and most probably inherited the βGlu6Val allele from his mother (who was heterozygous for HbS) in addition to the new mutation (βLys65Glu), which most probably occurred later on the
same chromosome 11 via spontaneous germ cell mutation. HbS-São Paulo gives positive solubility and sickling tests in consistency with the presence of HbS [βGlu6Val] substitution. However, HbS-São Paulo was faster than HbA in alkaline electrophoresis. In contrast, acid electrophoresis revealed similar electrophoretic mobility to HbS, but it is distinguishable from HbA and HbS by isoelectric focusing and HPLC. The βLys65Glu substitution conferred upon HbS-São Paulo structural instability with a significant reduction in oxygen affinity. HbS-São Paulo is functionally comparable to other low oxygen affinity variants, including HbS-Antilles, HbS-Cameroon, HbS-South End, and Hb Jamaica Plain as previously described. Despite being a simple heterozygote, the index case presented with moderate hemolytic and VO features of SCD attributed to the low oxygen affinity of HbS-São Paulo, which enhances desaturation, polymerization, red cell sickling, and the occurrence of clinical symptoms even in the heterozygotes. Hence, HbS-São Paulo is a dominant genetic trait. HbS-São Paulo is therefore a member of the so-called dominant/super-sickling non-S Hb variants with the other members being HbS-Antilles, HbS-Oman, and Hb Jamaica Plain. Because of its low affinity for oxygen, it can be predicted that HbS-São Paulo would produce clinically severe SCD if it is inherited as homozygous (HbS-São Paulo/HbS-São Paulo), double heterozygous with HbS (HbS-São Paulo/HbS), or β-thalassemia (HbS-São Paulo/β-thal) in the future.

CONCLUSION

To date, 14 non-S sickling Hb variants have been identified, characterized, and documented in the literature within a period of 46 years between 1966 and 2012. These atypical sickling Hb arose due to additional mutations that were superimposed on pre-existing HbS mutations (βGlu6Val) located on chromosome 11. Hence, the non-S sickling Hb variants are often described as double genetic mutants, some of which probably emanated from chromosomal crossing-over and translocation of a second (additional) gene onto chromosome 11 that carries a pre-existing HbS mutation. It is therefore not coincidental that the index cases of these atypical sickling variants were discovered in people of tropical, African, Mediterranean, and Asian regions within which pre-existing HbS mutation is very prevalent. Although the atypical sickling Hb variants are relatively rare, they are nonetheless clinically significant because they may produce hematological, VO, and other clinical manifestations in heterozygotes, double heterozygotes, or homozygotes depending on whether or not they are genetically recessive or dominant. These relatively rare non-S sickling Hb variants pose diagnostic difficulties because they quite often mimic the electrophoretic and chromatographic characteristics of the normal Hb (i.e., HbA) or one of the well-characterized abnormal Hb variants (such as HbS or HbC). Furthermore, some non-S sickling Hb variants may even exhibit alterations (low or high) in their oxygen affinity and dissociation profiles. Consequently, the probability of misdiagnosis is very high if only basic investigative techniques (e.g., sickling and solubility test, alkaline cellulose electrophoresis) are used for diagnosis, which is usually the case in low resource tropical laboratories. Therefore, the precise diagnosis of these mutant non-S sickling Hb variants may require more advance and elaborate diagnostic techniques such as acid agar gel Hb tetramer and globin chain electrophoreses, isoelectric focusing, HPLC, DNA and gene analysis, and determination of oxygen affinity and dissociation indices, most of which are regrettably not readily available in low resource laboratories of tropical countries. Paradoxically the tropical countries carry the highest prevalence and heaviest burden of sickle cell disorders in the world. Tropical countries must upgrade their investigative tools and techniques to diagnose hemoglobinopathies to avoid misdiagnosis of these atypical Hb mutations. Suffices to say that random mutations and generation of new mutant Hb variants are continuous natural processes; hence, many new non-S sickling Hb variants may emerge in the near or distant future. So, the onus lies on tropical, African, Mediterranean, and Asian clinicians, scientists, and hematologists to maintain a high clinical index of suspicion, sustain diligent scientific and hematological evaluations, and offer proactive genetic analysis and surveillance for prompt detection and diagnosis of any new non-S sickling Hb variants as soon as they emerge.
Disclosure
The authors declared no conflicts of interest. No funding was received from this study.

REFERENCES
1. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 1993 Mar;6(1):215-262.
2. Kaul DK, Fabry ME, Nagel RL. The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 1996 Mar;10(1):29-44.
3. Fleming AF, Storey J, Molinex L, Iroko EA, Attia ED. Abnormal haemoglobinbs in the Sudan savanna of Nigeria. 1. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol 1979 Apr;73(2):161-172.
4. Elguero E, Délédit-Loembe LM, Rougeron V, Arnathau C, Roche B, Becquart P, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci U S A 2011 Sep 20;108(12):4705-4709.
5. Olatunji PO. Malaria and the sickle gene: polymorphism balanced in favour of eradication. Ann Health Res 2018;4(2):88-96.
6. Gong L, Parikh S, Rosenthal PJ, Greenhouse B. Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J 2013 Sep;12(1):317-317.
7. Loggetto SR. Sickle cell anemia: clinical diversity and beta S-globin haplotypes. Rev Bras Hematol Hemoter 2013;35(3):155-157.
8. Wild BJ, Bain BJ. Investigation of abnormal haemoglobins and thalassaemia. In: Bain BJ, Bates I, l affan MA, l ewis MA, editors. Practical Haematology, 10th ed. London: Churchill Livingstone; 2012. p. 331-332.
9. Ahmed SG, Ibrahim UA. A compendium of pathophysiological basis of etiologic risk factors for painful vaso-occlusive crisis in sickle cell disease. Niger J Basic Clin Sci 2017;14(2):57-77.
10. Naik RP, Derebail VK. The spectrum of sickle hemoglobin-realted nephropathy: from sickle cell disease to sickle trait. Expert Rev Hematol 2017 Dec;10(12):1087-1094.
11. Barbedo MM, McCurdy PR. Red cell life span in sickle cell trait. Acta Haematol 1974;51(6):339-343.
12. Fernando C, Mendis S, Upasena AP, Costa y J, Williams JH, Moratuwagama D. Splenic disease in a young man at high altitude with undetected sickle cell disease. J Pediatr Hematol Oncol 2004 Nov;26(11):773-776.
13. Luo HY, Adewoye AH, Eung SH, Skelton TP, Quillen K, McMahon L, et al. A novel sickle hemoglobin: hemoglobin S-south end. J Pediatr Hematol Oncol 2004 Nov;26(11):773-776.
14. Keve A, Clark J, Zhang Y, Popowicz A, Manning JM, Neufeld EJ. Hemoglobin S-cameroon: a sickling hemoglobin with reduced oxygen affinity. N Engl J Med 2004 Oct;351(15):1532-1538.
15. Ducrocq R, Dratkowski P, Ithier G, Benkerrou M, Breton B, Elian J. A new major sickle cell syndrome: Hbs [beta6(A3)Glu–>Val;beta142[96(Glu–>Lys]. Hemoglobin 2004 May;28(2):131-135.
16. Zanella-Cleon I, Prévotu C, Joly P, Riou J, Becchi M, Wajcman H, et al. Strategy for identification by mass spectrometry of a new human hemoglobin variant with two mutations in Cis in the β-globin chain. Acta Haematol 2006;116:91-92.
17. Konotey-Ahulu FI, Gallo E, ll ehmann H, Ringelhann B. Haemoglobin S-Cameroon: a variant with amino acid substitutions in two residues of the β-polypeptide chain. FEBS J 2006;273:350-356.
by asparagine) showing one of the two amino acid substitutions of haemoglobin C Harlem. J Med Genet 1968 Jun;5(2):107-111.

35. Lang A, Lehmann H, McCurdy PR, Pierce L. Identification of haemoglobin C-Georgetown. Biochimica et Biophysica Acta (BBA)-Protein Structure 1972;278(1):57-61.

36. Adachi K, Kinney TR, Schwartz E, Asakura T. Molecular stability and function of Hb C-Harlem. Hemoglobin 1980;4(1):1-26.

37. O’Keeffe EK, Rhodes MM, Woodworth A. A patient with a previous diagnosis of hemoglobin S/C disease with an unusually severe disease course. Clin Hematol 2009 Jun;55(6):1228-1231, discussion 1231-1233.

38. Steinberg MH, Chui DH. HbC disorders. Blood 2013 Nov;122(2):3698.

39. Bookchin RM, Nagel RL, Ranney HM. Structure and properties of hemoglobin C-Harlem, a human hemoglobin variant with amino acid substitutions in 2 residues of the beta-polyepitope chain. J Biol Chem 1967 Jan;242(2):248-255.

40. Bookchin RM, Davis RP, Ranney HM. Clinical features of HbC-Harlem, a new sickling hemoglobin variant. Ann Intern Med 1968;68:8-18.

41. Moo-Penn W, Bechtel K, Jue D, Chan MS, Hopkins G, Schneider NJ, et al. The presence of hemoglobin S and C Harlem in an individual in the United States. Blood 1975 Sep;46(3):363-367.

42. Wong YS, Tanaka KR, Greenberg LH, Okada T. Hematuria associated with hemoglobin C-Harlem: a sickling hemoglobin variant. J Urol 1969 Dec;102(6):762-764.

43. Cromartie AD Jr, Hall DJ, Caldwell C. Pregnancy in a patient with hemoglobin C Harlem. Am J Obstet Gynecol 1979 Mar;133(5):582-584.

44. Boafor TK, Olavemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016 Apr;123(5):691-698.

45. Kawasaki K. Hemoglobin Yukushiki (Dhofar): E2 (58)beta proline yields arginine: structural and oxygen equilibrium studies of the variant found in two unrelated families. Fukuoka Igaku Zasshi 1974 Sep;65(9):622-635.

46. Hassan W, Basset P, Oudart JL, Goossens M, Rosa J. Properties of the double substituted hemoglobin C Ziguinchor a2A beta 6-2 (A3) Glu replaced by Val beta 58 (E2) Pro replaced by Arg) with a hereditary persistence of fetal hemoglobin (HPFH). Clinical and biological results. Med Trop (Mars) 1987 Apr-Jun;47(2):177-179.

47. Gardner K, Fulford T, Silver N, Rooks H, Angelis N, Allman M, et al. g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. Blood Adv 2018 Feb;2(3):235-239.

48. Romana M, Gérard N, Chout R, Krishnamoorthy R, Marianné-Pépin T. Origin of Hb S Antilles. Am J Hematol 2002 Aug;70(4):331-332.

49. Popp RA, Popp DM, Shippock SG, Yang MY, Mural JG, Aguinaga MP, et al. A transgenic mouse model of hemoglobin S Antilles disease. Blood 1997 Jun;89(11):4204-4212.

50. Fabry ME, Sengupta A, Suzuka SM, Costantini F, Rubin EM, Hofrichter J, et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and Hbs-Antilles results in increased phenotypic severity. Blood 1995 Sep;86(6):2419-2428.

51. Moo-Penn WF, Jue DL, Bechtel KC, Johnson MH, Schmidt RM. Hemoglobin Providence. A human hemoglobin variant occurring in two forms in vivo. J Biol Chem 1976 Dec;251(23):7575-7571.

52. Bardakiyan J, Leclerc L, Blouquit Y, Oulea O, Raaffaill D, Arous N, et al. A new case of hemoglobin Providence (a2 beta 82 (E6F) Lys----Asn or Asp) discovered in a French Caucasian family. Structural and functional studies. Hemoglobin 1985;9(4):333-348.

53. Bonaventura J, Bonaventura S, Sullivan B, Ferruzzi G, McCurdy PR, Fox J, et al. Hemoglobin Providence. Functional consequences of two alterations of the 2,3-diphosphoglycerate binding site at position beta 82. J Biol Chem 1976 Dec;251(23):7563-7571.

54. Nagel RL, Krishnamoorthy R, Pattoum S, Elion J, Gerard N, Romero J, et al. The erythrocyte effects of hemoglobin O(ARAB). Br J Haematol 1999 Dec;107(3):516-521.

55. Al Jadhany R, Makki H, Farrell G, Al Azzawi S. A case of compound heterozygosity for Hb S and Hb S Oman. Br J Haematol 2002 Mar;116(3):504-505.

56. Venugopal S, shaju A, Dhuri S, Al-Harthiy T, Jabal KB. Compound heterozygosity for HbS and HbS Oman: case report. Sultan Qaboos Univ Med J 2008 Nov;8(3):344-346.

57. Wali Y, AlBalushi H, Nazir HF. Sickle cell disease in Oman and HbS Oman: a brief review. Hematol Transfus Int 2017;4(6):142-143.

58. Sharma S, Sharma G, Chandra J, Colah R, Hemoglobin Agennogi--A rare abnormal beta globin chain variant. Indian J Pathol Microbiol 2016 Jan-Mar;59(1):99-101.

59. Harano T, Harano K, Ueda S, Imai K, Murabashi S, Hb Yamagata [beta 132(H10)lys----Asn]: a new abnormal hemoglobin in a Japanese family. Hemoglobin 1990;14(2):207-211.

60. Ferrault J, Fairbanks VF, McCormick DJ, Kubik K, Madden BJ, Holmes MW, et al. Hemoglobin Rockford. 568(E12)Leu-->Phe: a new Hb variant associated with mild anemia. Blood 1997;90(10):2822.

61. Ferreira C, Hoyer JD, Miranda A, Picanço I, Almendra V, Seixas MT, et al. Hemoglobin Loves Park [568 (E12) Leu-->Phe]: report of five cases including one originating from a de novo mutation. Am J Hematol 2006 Apr;81(4):256-261.

62. Bouzid K, Odeïève MH, Ither G, Benkerrou M, Couque N, Elion J, et al. Atypical sickle cell syndromes: a report on two cases. Immunol Anai Biol Spec 2011;26(5-6):267-275.

63. Owen MC, Ockelford PA, Wells RM. Hb Howick [beta 37(C3)Trp-->Gly]: a new high oxygen affinity variant of the alpha 1 beta 2 contact. Hemoglobin 1993 Dec;17(6):513-521.

64. Corbett JD, Mickels WE, Maestre MF. Effect of hemoglobin concentration on nucleation and polymer formation in sickle red blood cells. J Biol Chem 1995 Feb;270(6):2708-2715.